Premium
Angiotensin‐converting enzyme polymorphism gene and evolution of nephropathy to end‐stage renal disease
Author(s) -
ORTIZ M Angels,
DE PRADO Anna,
DOÑATE Teresa,
GALLART Lluis,
CLARAMUNT Helena,
HERNÁNDEZ Marta,
MARTÍNEZ Joaquin,
MARTÍNEZ Esther,
POU Jose M
Publication year - 2003
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1046/j.1440-1797.2003.00165.x
Subject(s) - medicine , nephropathy , genotype , renal function , diabetic nephropathy , gastroenterology , endocrinology , angiotensin converting enzyme , gene polymorphism , kidney disease , nephrology , end stage renal disease , urology , kidney , disease , diabetes mellitus , gene , genetics , biology , blood pressure
SUMMARY: Genetic polymorphisms of the renin‐angiotensin system (RAS) have been implicated in the pathogenesis of nephropathy and end‐stage renal disease (ESRD). The association between angiotensin‐converting enzyme (ACE) gene polymorphism and nephropathy evolution was studied. A random sample of 161 subjects from the Nephrology Department (of Hospital de Sant Pau) were divided into two groups: (i) 117 with end‐stage renal disease; (ii) 44 with established nephropathy; and (iii) control groups of 129 subjects. The ACE gene polymorphism was performed by using polymerase chain reaction. High DD genotype presentation was observed in the two groups of subjects with nephropathy (46.12 and 61.37%, respectively vs 35.66% in controls; P < 0.0482), and also, a decrease was observed in the II genotype (6.4 and 4.54%, respectively vs 13.17% in controls, P < 0.0404). Glomerular filtration rate (GFR) was evaulated after 44 months of follow up. An important decrease of GFR was observed in patients with DD polymorphism versus other genotypes (initial, 32.3 ± 7.9 and at 44 months, 18.35 ± 3.3 mL/min vs 31.4 ± 11.9 and 11.7 ± 3.2 mL/min; P < 0.039). In a non‐longitudinal study of patients in ESRD, patients with an ACE‐DD genotype had a lower period of time between diagnosis of nephropathy and ESRD than patients with other genotypes (10.45 ± 9.32 vs 19.5 ± 8.4 years; P < 0.034). In conclusion, the ACE gene that controls RAS response may influence the development and progression of nephropathy to ESRD. Patients who develop several types of nephropathy have a higher risk of severe evolution if they have a profile of ACE‐DD genotype.